Pfizer said Monday data from a new trial show its COVID-19 vaccine is safe for kids ages 5 to 11, and it will file with regulators as soon as possible for expanded approval. Pfizer said kids in the trial had a similar antibody response to young adults ages 16 to 25 in a previous study. The younger kids were given about one-third the dose of the older group. “Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. – underscoring the public health need for vaccination. These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency,” Pfizer’s CEO Albert Bourla said in a statement. To read the full story.